Buy Ranbaxy Laboratories, says Sukhani

Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "Aurobindo Pharma, Sun Pharmaceutical Industries and Glenmark Pharma are attractive opportunities. Glenmark has gone through a deep correction. Sun Pharma is already on a roll and there is more there and if you have the courage buy Ranbaxy Laboratories even at current levels."

At 11:15 hrs Ranbaxy Laboratories was quoting at Rs 626.90, down Rs 7.20, or 1.14 percent.

The share touched its 52-week high Rs 667.30 and 52-week low Rs 306.05 on 03 September, 2014 and 27 January, 2014, respectively.